Loading
A phase 3 trial of AZD0486 in chronic lymphocytic leukaemia, run by AstraZeneca, now recruiting.
Surovatamig as Consolidation Therapy in Participants With Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated Immunoglobulin Heavy Chain Variable (IGHV) is a phase 3 interventional study registered as NCT07509151 by AstraZeneca, with 420 participants planned, started 2026-05-05 and due to reach its primary completion in 2031-08-29. Interventions recorded: Surovatamig. Conditions listed: Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated IGHV. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares AZD0486, AstraZeneca.
Shares AZD0486, AstraZeneca.
Shares AZD0486, AstraZeneca.
Shares AZD0486, Chronic lymphocytic leukaemia, AstraZeneca.
Shares Chronic lymphocytic leukaemia, first treatment, Chronic lymphocytic leukaemia, AstraZeneca.
Shares Chronic lymphocytic leukaemia, first treatment, Chronic lymphocytic leukaemia, AstraZeneca.
Shares Chronic lymphocytic leukaemia, first treatment, Chronic lymphocytic leukaemia.
Shares Chronic lymphocytic leukaemia, first treatment, Chronic lymphocytic leukaemia.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/